Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialised care setting in Spain. Application to the cost-effectiveness of two drugs frequency used in its treatment

J. Carballido, J. L. Ruiz-Cerdá, M. Unda, V. Baena, P. Campoy, J. Manasanch, Eric John Slof

    Research output: Contribution to journalArticleResearchpeer-review

    7 Citations (Scopus)

    Abstract

    Objectives: To develop a pharmacoeconomic study in order to know the average cost of BPH diagnosis and follow-up in Spain in the Urology Department setting from the perspective of the public health system, considering two frequently used drugs in the Spanish Healthcare environment, an alpha-blocker (tamsulosin) and the lipido-sterolic extract of Serenoa repens (Permixon®). Material and methods: Direct healthcare costs of BPH diagnosis and treatment were determined for each clinical stage according to the International Prostate Symptom Score (IPSS): mild, moderate and severe. Data on the usage and unit costs of healthcare resources were obtained from a semi-structured interview with clinical experts. The clinical efficacy of the medical treatments was obtained from the PERMAL clinical study, where therapeutic equivalence between the two studied drugs was observed. Results: For patients treated in the Urology Department setting, the average annual cost of diagnostic tests and medical visits related to mild, moderate or severe BPH symptoms were, respectively, € 124, € 207, and € 286. The average annual cost of the drugs, including adverse effects treatment, was € 211 for Permixon® and € 346 for tamsulosin. Discussion: Costs of medical care of BPH increases with symptom intensity. Pharmacological treatment makes up a significant part of the disease's cost. According to the model used, treatment with Permixon® is considerably more cost-effective than with tamsulosin, offering average yearly savings of € 135 per patient.
    Original languageEnglish
    Pages (from-to)916-925
    JournalActas Urologicas Espanolas
    Volume32
    Issue number9
    Publication statusPublished - 1 Jan 2008

    Keywords

    • Benign prostatic hyperplasia
    • Cost effectiveness analysis
    • Drug therapy
    • Healthcare resources
    • Serenoa repens
    • Tamsulosin

    Fingerprint Dive into the research topics of 'Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialised care setting in Spain. Application to the cost-effectiveness of two drugs frequency used in its treatment'. Together they form a unique fingerprint.

    Cite this